Caspian Therapeutics launches with $50M funding and Eli Lilly backing to develop menin inhibitor for diabetes
Caspian Therapeutics has been created as a spin-out from Kura Oncology to advance a menin-targeting drug for diabetes.
The company received $50 million in initial capital, led by BVF Partners with participation from Kura, Eli Lilly and other investors.
The lead candidate, KO-7246, is an oral small-molecule menin inhibitor that aims to increase the number and activity of pancreatic beta cells, potentially boosting insulin production.
Funding will support IND-enabling work and early proof-of-concept studies, and Caspian also plans to develop a second menin blocker for diabetes and cardiometabolic diseases, though details are limited.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that